DERMOTIC (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 1988.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
DERMOTIC is a topical otic corticosteroid containing fluocinolone acetonide, a medium-potency glucocorticoid that reduces inflammation and immune response in the ear canal. It is administered as an oil/drop formulation and works by binding to corticosteroid hormone receptors to suppress inflammatory cytokine production. The drug is indicated for inflammatory and allergic conditions of the external and middle ear.
With LOE approaching and minimal Part D penetration ($33K annually), this mature product is likely supported by a lean, maintenance-focused commercial team focused on retention rather than expansion.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Worked on DERMOTIC at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
DERMOTIC offers limited career advancement opportunities given its LOE-approaching status and minimal external hiring signal (zero linked jobs). Roles available are typically defensive brand management, generic defense sales, or medical affairs support focused on maintaining existing market position rather than driving growth.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo